Boston Scientific’s ACURATE neo2 Aortic Valve System failed to meet its primary endpoint in the ACURATE IDE trial, resulting in a decline in the company’s stock price. The trial compared the ACURATE neo2 valve to competitor valves from Edwards Lifesciences and Medtronic, but the ACURATE neo2 failed to demonstrate non-inferiority in terms of mortality, stroke, or rehospitalization at one year. Despite this setback, the company highlighted positive results from a post-hoc analysis, and it continues to work with the FDA for U.S. approval.